IP Library › Granted Patent US 8,642,311
Granted Patent B2
US 8,642,311 · App. 13/601,174 · Granted Feb 4, 2014

Thymidine kinase

Inventors: Marina Radrizzani (Milan, IT); Salvatore Toma (Milan, IT); Francesca Salvatori (Milan, IT); Stefania Massa (Milan, IT)
Assignee: MolMed SpA
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,642,311
App. No.
13/601,174
Granted
Feb 4, 2014
Kind
B2
Abstract

A polynucleotide comprising a nucleotide sequence encoding a thymidine kinase wherein at least one of the nucleotides corresponding to the splice donor site nucleotides is replaced by another nucleotide and wherein the nucleotides of the splice acceptor sites are not altered.

Claims (42)

1. An isolated polynucleotide comprising the polynucleotide as set forth in SEQ ID NO: 2.

2. A vector comprising the polynucleotide of claim 1 .

3. A host cell comprising the polynucleotide of claim 1 .

4. A host cell comprising the vector of claim 2 .

5. A pharmaceutical composition comprising the polynucleotide of claim 1 and a pharmaceutically acceptable carrier.

6. A pharmaceutical composition comprising the vector of claim 2 and a pharmaceutically acceptable carrier.

7. A kit comprising:

(i) the polynucleotide of claim 1 ; and

(ii) ganciclovir.

8. A kit comprising:

(i) the vector of claim 2 ; and

(ii) ganciclovir.

9. A kit comprising:

(i) the host cell of claim 3 ; and

(ii) ganciclovir.

10. A kit comprising:

(i) the host cell of claim 4 ; and

(ii) ganciclovir.

11. A kit comprising:

(i) the pharmaceutical composition of claim 5 ; and

(ii) ganciclovir.

12. A kit comprising:

(i) the pharmaceutical composition of claim 6 ; and

(ii) a substantially non-toxic agent which is converted by thymidine kinase into a toxic agent.

13. A kit comprising:

(i) the polynucleotide of claim 1 ; and

(ii) acyclovir.

14. A kit comprising:

(i) the polynucleotide of claim 1 ; and

(ii) trifluorothymidine.

15. A kit comprising:

(i) the polynucleotide of claim 1 ; and

(ii) 1-[2-deoxy, 2-fluoro, β-D-arabino furanosyl]-5-iodouracil.

16. A kit comprising:

(i) the polynucleotide of claim 1 ; and

(ii) adenine arabinoside (ara-A).

17. A kit comprising:

(i) the polynucleotide of claim 1 ; and

(ii) idoxuridine.

18. A kit comprising:

(i) the polynucleotide of claim 1 ; and

(ii) arabinofuranosyl cytidine (Ara C).

Priority Claims (1)
GB 0413702.2 · Jun 18, 2004 · national
Continuity (2)
Continuation 11629962
Related Publication 20130028876A1 · Jan 31, 2013